Review of CJC-1295 DAC – Buy CJC-1295 with DAC 2mg Peptide (USA Made)
07June 7, 2023
Review of CJC-1295 DAC – Buy CJC-1295 with DAC 2mg Peptide (USA Made)
CJC-1295 DAC, also known as CJC-1295 with Drug Affinity Complex, is a synthetic peptide belonging to the class of growth hormone-releasing hormones (GHRH). It is a modified form of the naturally occurring peptide hormone called growth hormone-releasing hormone (GHRH).
At Loti Labs, we pride ourselves on stocking high-quality research chemicals. Buy CJC-1295 DAC for research purposes only and not for human consumption. It is available in lyophilized powder form and sold in 2 mg vials.
WHAT IS CJC-1295 DAC
CJC-1295 DAC is a synthetic tetra-substituted peptide designed to stimulate the release of growth hormone from the pituitary gland of research animals.
One notable feature of CJC-1295 DAC is its prolonged half-life, which means it remains active in the body for an extended period compared to other GHRH peptides. This is achieved through the addition of a “drug affinity complex” (DAC), which allows CJC-1295 DAC to bind to serum albumin and extend its activity.
Studies show that CJC-1295 DAC binds to and activates specific receptors in the brain, increasing the production and release of growth hormones.
After administering CJC-1295 DAC on animal test subjects, it reduced the production of Dipeptidyl Aminopeptidase-IV (DPP-IV) enzyme (an antigenic enzyme involved in signal transduction, apoptosis or programmed cell death, and immune system regulation).
CJC-1295 DAC has a half-life of approximately eight (8) days.
CJC-1295 DAC: A Synthetic 29 Amino Acid Analog of GHRH
CJC-1295 DAC is a synthetic peptide consisting of 29 amino acids, designed as an analog of the naturally occurring Growth Hormone-Releasing Hormone (GHRH). This structural modification enhances its stability and efficacy in stimulating the release of growth hormone from the pituitary gland. The inclusion of the Drug Affinity Complex (DAC) further extends its half-life, allowing for prolonged activity and sustained growth hormone release. This makes CJC-1295 DAC a powerful tool in research settings, as it effectively mimics the natural hormone’s action, leading to increased IGF-1 levels, improved protein synthesis, and enhanced body composition. Its ability to normalize growth in GHRH knockout mice underscores its potential as a therapeutic agent for growth hormone deficiencies.
Mechanism of Action and Benefits
CJC-1295 with DAC operates by mimicking the natural Growth Hormone-Releasing Hormone (GHRH), effectively stimulating the pituitary gland to release growth hormone (GH). The inclusion of the Drug Affinity Complex (DAC) is a game-changer, as it extends the peptide’s half-life, ensuring a sustained release of GH over time. This prolonged effect is crucial as it leads to elevated levels of Insulin-like Growth Factor-1 (IGF-1), a pivotal player in promoting growth and development.
Research has shown that CJC-1295 with DAC can completely normalize growth in GHRH knockout mice, underscoring its potential as a therapeutic agent. The peptide’s ability to increase lean mass and improve body composition makes it a promising candidate for addressing growth hormone deficiencies. Additionally, the rise in IGF-1 levels facilitated by CJC-1295 with DAC enhances protein synthesis, contributing to overall health and well-being.
CJC-1295 DAC GROWTH HORMONE EFFECTS
CJC-1295 DAC peptide can dramatically increase Growth Hormone and Insulin-like Growth Factor 1. The effects of which are:
Increased muscle mass and muscle growth
Fat loss
Improved bone density
Enhanced immune function
CJC-1295 DAC SIDE EFFECTS
Below are what researchers noticed during clinical trials with CJC-1295 DAC’s use in animal test studies.
Anxiety
Irritability
Nausea
Comparison to CJC-1295
CJC-1295 with DAC is an enhanced version of the original CJC-1295 peptide, distinguished by the addition of the Drug Affinity Complex (DAC). This modification significantly extends the peptide’s half-life, allowing for more sustained GH release and higher IGF-1 levels. Compared to CJC-1295, the DAC variant boasts a longer duration of action and increased potency.
Research indicates that CJC-1295 with DAC is more effective at normalizing growth in GHRH knockout mice than its predecessor. The DAC component not only improves the peptide’s stability but also enhances its bioavailability, making CJC-1295 with DAC a more robust and effective therapeutic agent.
Selective Receptor Affinity of CJC-1295 with DAC in In Vitro Studies
CJC-1295 with DAC has been shown to demonstrate selective receptor affinity in various in vitro studies. This peptide, a modified analog of the naturally occurring Growth Hormone-Releasing Hormone (GHRH), exhibits a high degree of specificity in binding to its target receptors. The inclusion of the Drug Affinity Complex (DAC) enhances its ability to bind effectively to the growth hormone-releasing hormone receptors, ensuring a more sustained and potent stimulation of growth hormone (GH) release.
In vitro studies have highlighted that CJC-1295 with DAC binds selectively to receptors in the pituitary gland, leading to a significant increase in GH release. This selective receptor affinity is crucial for its effectiveness, as it allows for precise targeting and minimal off-target effects. The peptide’s ability to maintain this specificity while extending its half-life makes it an invaluable tool in research settings, where understanding the nuances of GH release is essential.
The findings from these studies underscore the potential of CJC-1295 with DAC as a therapeutic agent, particularly in conditions where growth hormone deficiency is a concern. By demonstrating selective receptor affinity, CJC-1295 with DAC not only enhances GH release but also contributes to the normalization of growth and improved body composition, as evidenced in GHRH knockout mouse models.
Potential of CJC-1295 DAC in Enhancing Growth Hormone Levels
CJC-1295 DAC has shown remarkable potential in increasing growth hormone levels in research models. Studies indicate that this peptide can elevate growth hormone levels by 2- to 10-fold, making it a powerful tool in research settings. This significant increase is primarily due to the peptide’s ability to bind to specific receptors in the pituitary gland, facilitated by the Drug Affinity Complex (DAC), which extends its half-life and enhances its efficacy.
The dramatic rise in growth hormone levels observed with CJC-1295 DAC administration underscores its potential as a therapeutic agent, particularly for conditions characterized by growth hormone deficiencies. By boosting growth hormone levels, CJC-1295 DAC contributes to improved IGF-1 levels, enhanced protein synthesis, and better overall body composition. These effects are particularly evident in GHRH knockout mice models, where the peptide has been shown to completely normalize growth.
Overall, the ability of CJC-1295 DAC to significantly increase growth hormone levels highlights its value in scientific research and its potential therapeutic applications.
Research and Clinical Studies
CJC-1295 with DAC has been extensively studied in various research settings, both in vitro and in vivo. These studies have consistently demonstrated the peptide’s ability to stimulate GH release and elevate IGF-1 levels. Notably, research has shown that CJC-1295 with DAC can completely normalize growth in GHRH knockout mice, highlighting its potential as a treatment for growth hormone deficiency.
Clinical studies further support the efficacy of CJC-1295 with DAC. For instance, a study published in the Journal of Physiology and Endocrinology and Metabolism found that once daily administration of the peptide increased IGF-1 levels and improved body composition in healthy subjects. Intermediate results from this study, presented at the annual meeting of the Endocrine Society, underscore the peptide’s therapeutic benefits.
Another study by Fintini et al. demonstrated that CJC-1295 with DAC effectively increased GH release and IGF-1 levels in healthy subjects. These findings reinforce the peptide’s potential as a therapeutic agent for growth hormone deficiency, showcasing its ability to stimulate GH release and improve overall body composition.
Overall, the body of research and clinical studies on CJC-1295 with DAC highlights its significant therapeutic benefits and efficacy in stimulating GH release and increasing IGF-1 levels.
LOOKING FOR WHERE TO BUY CJC-1295 DAC ONLINE
When searching for research peptides online, it is paramount to buy from a trusted laboratory to ensure the integrity of your research.
Loti Labs offers affordable prices that come with quality control reports. We have in-depth customer support and a generous return policy when you buy CJC-1295 DAC for sale.
Visit our website or contact us today to buy CJC-1295 DAC online.
Alba, M. et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology, Endocrinology, and Metabolism.
Jette, L. et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.
Benquet, C. et al. (2004). (CJC-1295 (DAC-GRF), a long-acting GRF analog, enhances pulsatile GH secretion, increases IGF-I levels, and restores linear growth. Program of the 86th Annual Meeting of the Endocrine Society, New Orleans, LA, p 491 (Abstract P3-109).
Teichman, Sam L., Neale, Ann, Lawrence, Betty, Gagnon, Catherine, Castaigne, Jean-Paul, & Frohman, Lawrence A. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. https://doi.org/10.1210/jc.2005-1536.
